

Genetic Insights on Non-Alcoholic Fatty Liver Disease (NAFLD): A Comprehensive Review

Syeda Sana

University of Health Sciences

Abstract

30–32 percent of the total population worldwide suffers from non-alcoholic fatty liver disease (NAFLD). It includes a continuum with conditions such as simple steatosis, non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. The conventional wisdom has long believed that such lifestyle-related factors as overconsumption of calories, inactive behavior, and insulin resistance are the key perpetrators of its development. Nevertheless, there is mounting evidence that genetic predisposition, epigenetic alterations, and gut microbiome interactions are vital factors that determine the susceptibility, progression, and outcome of this disease. Genetic variations influence the regulation of lipids, inflammation, and fibrosis, while epigenetic modifications impact diet, obesity, and early-life exposures through mechanisms such as DNA methylation, histone modifications, and the actions of non-coding RNAs, often resulting in long-term consequences. Meanwhile, the loss of intestinal barrier integrity in gut microbial dysbiosis exacerbates hepatic disease in a reciprocally reactive relationship with host genetic components. Collective insight from all three disciplines genetics, epigenetics, and microbiome provides healthy insight into the pathophysiology of NAFLD to identify potential opportunities to discover biomarkers, stratified risks, and precision medicine-based interventions. New and promising treatment products, such as targeted dietary supplements, enteric microbiota manipulation, and epigenetic reset, support the possible comparison of primary and individualized interventions to minimize the worldwide NAFLD problem.

Key words:NAFLD, biomarkers of liver, chronic liver disease,fatty liver disease, epigenetics of liver disease,genetic factors

Submitted on 12-11-2025– Revised on 13-12-2025– Accepted on 20-02-2026 Published on 13-3-26

1. INTRODUCTION

NAFLD has become the most common chronic liver disease in the whole world, with an approximate occurrence of nearly 25 percent among adult people (Younossi et al., 2016). The disease is traditionally viewed as an obesity- and insulin-resistance-related metabolic complication; however, the understanding of it is expanding due to the significant role of the environmental and genetic factors (Loomba et al., 2015). Studies of familial aggregation

and twin research have found the heritability of hepatic steatosis to be as much as 70 percent, indicating a substantial genetic factor.

The range of diseases goes from isolated steatosis and NASH to eventual cirrhosis or hepatocellular carcinoma. Most patients diagnosed with simple steatosis are asymptomatic, although those that develop NASH and fibrosis are at a much greater risk of dying due to liver-related issues. The silence of the disease in most cases makes diagnosis

late after the development of complications.

In the latest genome-wide association studies (GWAS), a number of genetic loci have been found with a strong correlation to the presence of hepatic lipid accumulation, inflammation, and fibrosis. They are PNPLA3, TM6SF2, MBOAT7, and GCKR, and each of them has its individual metabolic impacts (Speliotes et al., 2011; Luukkonen et al., 2016). Moreover, HSD17B13 protective alleles are associated with reduced chances of inflammation and fibrosis (Abul-Husn et al., 2018).

Epigenetics has further added to this knowledge and identified the way gene expression can be modified by reversible, heritable alterations in the absence of variation in DNA sequence. The levels of methylation and alterations in the chromatin structure can be altered by maternal diet, obesity, early-life stress, and environmental toxins, which can affect susceptibility even through subsequent generations (Marco et al., 2014).

Lastly, the gut microbiome, which has trillions of microorganisms, influences it through the gut-liver axis. It controls the host immunity, metabolism, and inflammation, and host genetics controls it (Goodrich et al., 2016).

2. Comparative Overview

● Similarities

Both are significant problems of chronic liver damage.

Similar histological findings: steatosis, inflammation, ballooning cells, and fibrosis of the liver.

May go on to develop cirrhosis and carcinoma.

Differences

Etiology:

AFLD: It is a condition caused by chronic intake of alcohol i.e. oxidative stress, acetaldehyde toxicity, inflammation.

NAFLD: the condition develops in the absence/minimal alcohol consumption - > associated with obesity, insulin resistance, diabetes type 2, dyslipidemia.

Prevalence:

AFLD: Limit to people using alcohol.

NAFLD Affects an estimated 25 percent of the world population because of increased metabolic syndrome.

Biochemical Markers:

AFLD: AST/ ALT ratio is normally greater than 2. Early raised ALT.

Genetic Factors:

AFLD: Variant versions of alcohol metabolism genes (ADH1B, ALDH2).

NAFLD: PNPLA3, TM6SF2, MBOAT7 polymorphisms Regulation of: lipid metabolism fibrosis inflammation.

Epigenetics & Microbiome


:Both are subject to alterations in their epigenomics as well as the microbiome (gut dysbiosis).

More thoroughly explored in NAFLD in metabolic grounds.

Treatment:

AFLD: Total abstinence is the primary care.

NAFLD: Dietary change, weight loss, lifestyle, and pharmacological.



3. Epigenetic Alterations Reacting to NAFLD

3.1 DNA methylation

Mechanism:

Hypermethylation or hypomethylation changes metabolic and inflammatory gene expression.

Examples:Hypermethylation

PPARalpha, FGF21, and SIRT1 inhibits fatty acid oxidation, which is a cause of steatosis.Hypomethylation in inflammatory cytokines such as TNF-alpha and IL-6 intensifies chronic inflammation (Sookoian & Pirola, 2013).

Clinical Implication:

Altered methylation profiles may be used as blood NAFLD biomarkers of early disease detection and staging.

3.2 Modification of Histone

Mechanism:

Histone acetylation (and deacetylation) makes chromatin accessible and allows the activity of metabolic genes.

Examples:

Decreased activity of SIRT1 and HDAC3 leads to increased acetylation of histones, which activates the expression of lipogenic and fibrogenic genes (Zhou et al., 2020).

Clinical Implication:

HDAC inhibitors and SIRT1 activators seem to be on the developmental horizons as potential therapeutic agents that would help to restore histone distribution to mitigate the disease development rates in NAFLD.

3.3 lncRNAs and microRNAs

Mechanism: Aberrant microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have roles in lipid metabolism, apoptosis, and fibrosis.

Examples:

- 1 Mir-122, mir-34a, and mir-21 are associated with steatosis, apoptotic, and fibrotic signaling.
- 1 Efforts have been made to identify MEG3, HULC, and MALAT1 among lncRNAs that can modulate inflammatory and fibrosis-related pathways (Chen et al., 2018).

Clinical Implication:

Both miR-122 and miR-34a are circulating biomarkers under clinical investigation.

The clinical application of therapeutics, similar to SNAs derived from these therapeutics, is primarily in the preclinical stage but represents a promising direction for the future.

3.4

Epigenetics—Between Generations

Mechanism: The metabolic condition of the maternal parent leaves permanent modifications on the fetus in the form of epigenetic tags.

Example:

- 1 Gestational diabetes and maternal obesity in fetal liver whose hepatic gene methylation is distorted, exposing the victim offspring to being susceptible to NAFLD (Marco et al., 2014).

Clinical Implication This highlights the importance of early-life interventions and maternal health programs as a potential strategy to mitigate the risk of transgenerational NAFLD.

3.5 Potential of Therapeutics

Mechanism:

Epigenetic therapies are treatments that were designed to reverse adverse gene regulation.

Examples:

Hypothetically, HADAC inhibitors can be used to prevent fibrosis and lipogenesis.

The drugs coming are based on IRNA, with the aim of targeting the pathways of the disease.

Clinical Implication:

Epigenetic therapies are promising but thus far are primarily in early-stage testing; combination with lifestyle intervention will be an important aspect.

4. Gut Microbiota and NAFLD

4.1 Barrier Dysfunction and Dysbiosis

Mechanism:

NAFLD is linked with a low level of microbial diversity and a state of imbalance (dysbiosis). Industrialized food increases Firmicutes and Proteobacteria, thus leading to a disruption of the gut-liver axis.

Example:

Dysbiosis promotes intestinal permeability (leaky gut) and the translocation of endotoxin (LPS) into the bloodstream.

Clinical Impression:

Endotoxemia induces a whole-body and hepatic inflammatory response, and epithelial barrier maintenance in the gut is a potential therapeutic target in early-stage NAFLD.

4.2 Metabolites of microbes

Mechanism:

The metabolites produced by microbes regulate the metabolism of hepatic glucose and lipids.

Examples:

- 1 Short-chain fatty acids (SCFAs) are notable to increase insulin sensitivity such as butyrate.

The shifted bile acid metabolism and the compromised FXR signaling adversely affect lipid metabolism (Boursier et al., 2016).

Clinical Implication: SCFA regulation and the bile acid-FXR pathway are emerging as metabolic interventions for NAFLD.

4.3 Genetic Interaction of Host and Microbiome

Mechanism:

Microbial composition and gut Hepatic liver communication is produced by host genetics.

Examples:

Anemia-related FUT2 variants modify the colonization of intestinal microbes.

The PNPLA3 variants can have an effect on microbiome interactions and worsen NAFLD (Goodrich et al., 2016).

Clinical Implication: Combining genomic and microbiome data can help make individualized NAFLD risk estimates and therapeutics.

4.4 Microbiota Therapies

Mechanism:

The balance of microbes can be corrected in a potential reversal of the disease.

Examples:

Probiotics (e.g., *Lactobacillus*, *Akkermansia*), prebiotics, and fecal microbiota transplantation (FMT) are in development.

Clinical Implication:

The contribution of microbiota-directed therapies as adjunctive interventions to diet and lifestyle change remains inconclusive, but there is potential in the future.

3. Epigenetic Alterations Reacting to NAFLD

3.1 DNA methylation

Mechanism:

Hypermethylation or hypomethylation changes metabolic and inflammatory gene expression.

Examples:

Hypermethylation of PPARalpha, FGF21, and SIRT1 inhibits fatty acid oxidation, which is a cause of steatosis. Hypomethylation in inflammatory cytokines such as TNF-alpha and IL-6 intensifies chronic inflammation (Sookoian & Pirola, 2013).

Clinical Implication:

Altered methylation profiles may be used as blood NAFLD biomarkers of early disease detection and staging.

3.2 Modification of Histone

Mechanism:

Histone acetylation (and deacetylation) makes chromatin accessible and allows the activity of metabolic genes.

Examples:

Decreased activity of SIRT1 and HDAC3 leads to increased acetylation of histones, which activates the expression of lipogenic and fibrogenic genes (Zhou et al., 2020).

Clinical Implication: HDAC inhibitors and SIRT1 activators seem to be on the developmental horizons as potential therapeutic agents that would help to restore histone distribution to mitigate the disease development rates in NAFLD.

3.3 lncRNAs and microRNAs

Mechanism: Aberrant microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have roles in lipid metabolism, apoptosis, and fibrosis.

Examples:

1 Mir-122, mir-34a, and mir-21 are associated with steatosis, apoptotic, and fibrotic signaling.

1 Efforts have been made to identify MEG3, HULC, and MALAT1 among lncRNAs that can modulate inflammatory and fibrosis-related pathways (Chen et al., 2018).

Clinical Implication:

Both miR-122 and miR-34a are circulating biomarkers under clinical investigation.

The clinical application of therapeutics, similar to SNAs derived from these therapeutics, is primarily in the preclinical stage but represents a promising direction for the future.

3.4 Epigenetics—Between Generations

Mechanism: The metabolic condition of the maternal parent leaves permanent modifications on the fetus in the form of epigenetic tags.

Example:

Gestational diabetes and maternal obesity can distort hepatic gene

methylation in the fetal liver, making the affected offspring susceptible to NAFLD (Marco et al., 2014).

Clinical Implication This highlights the importance of early-life interventions and maternal health programs as a potential strategy to mitigate the risk of transgenerational NAFLD.

3.5 Potential of Therapeutics

Mechanism: Epigenetic therapies are treatments that were designed to reverse adverse gene regulation.

Examples:

Hypothetically, HADAC inhibitors can be used to prevent fibrosis and lipogenesis.

The drugs coming are based on IRNA, with the aim of targeting the pathways of the disease.

Clinical Implication: Epigenetic therapies are promising but thus far are primarily in early-stage testing; combination with lifestyle intervention will be an important aspect.

4. Gut Microbiota and NAFLD

4.1 Barrier Dysfunction and Dysbiosis

Mechanism: NAFLD is linked with a low level of microbial diversity and a state of imbalance (dysbiosis). Industrialized food increases Firmicutes and Proteobacteria, thus leading to a disruption of the gut-liver axis.

Example: Dysbiosis promotes intestinal permeability (leaky gut) and the translocation of endotoxin (LPS) into the bloodstream.

Clinical Impression: Endotoxemia induces a whole-body and hepatic inflammatory response, and epithelial barrier maintenance in the gut is a

potential therapeutical target in early-stage NAFLD.

4.2 Metabolites of microbes

Mechanism: The metabolites produced by microbes regulate the metabolism of hepatic glucose and lipids.

Examples:

1 Short-chain fatty acids (SCFAs) are notable to increase insulin sensitivity such as butyrate.

The shifted bile acid metabolism and the compromised FXR signaling adversely affect lipid metabolism (Boursier et al., 2016).

Clinical Implication:

SCFA regulation and the bile acid-FXR pathway are emerging as metabolic interventions for NAFLD.

4.3 Genetic Interaction of Host and Microbiome

Mechanism:

Microbial composition and gut Hepatic liver communication is produced by host genetics.

Examples:

Anemia-related FUT2 variants modify the colonization of intestinal microbes.

The PNPLA3 variants can have an effect on microbiome interactions and worsen NAFLD (Goodrich et al., 2016).


Clinical Implication: Combining genomic and microbiome data can help make individualized NAFLD risk estimates and therapeutics.

4.4 Microbiota Therapies

Mechanism: The balance of microbes can be corrected in a potential reversal of the disease.

Examples: Probiotics (e.g., Lactobacillus, Akkermansia), prebiotics, and fecal microbiota transplantation (FMT) are in development.

Clinical Implication: The contribution of microbiota-directed therapies as adjunctive interventions to diet and lifestyle change remains inconclusive, but there is potential in the future.



5. Clinical Implications

The knowledge of these pathways has revolutionized practices in the clinics:

Risk Stratification: A risk assessment of fibrosis can be performed by means of genotyping PNPLA3, TM6SF2, and HSD17B13.

Diagnostics: Circulating miRNAs and patterns of DNA methylation are being developed into non-invasive markers (Sookoian & Pirola, 2013).

Therapy: Genotypes that are at high risk might profit from earlier or more forceful treatment.

Precision Nutrition: Genetics and microbiome-based diets work better (Krawczyk et al., 2018).

Pharmacogenomics: FXR agonists, HDAC inhibitors, and miRNA perturbations are in trial.

4. CONCLUSION

Non-alcoholic fatty liver disease (NAFLD) can be considered as a paradigmatic example of a pathological process that is determined by a complex

interplay between hereditary predisposition, microepigenomic reprogramming, and microbiome. The metabolic syndrome, widely viewed as a hepatic manifestation, is considered the predecessor of NAFLD as a multisystem disorder with pathobiologically unique drivers in every patient. Population-based recommendations are being changed into individualized ones that will be dependent on genetic and molecular profiles.

The major development in the field of genome-wide association studies, epigenome mapping, and microbiome sequencing has enabled us significantly to realize progress and heterogeneity of NAFLD. The identification of specific gene variants, such as PNPLA3 or TM6SF2, has reshaped risk evaluation, and it will be interesting to see how, in the future, circulating epigenetic biomarkers and microbial metabolites will be used as the potential non-invasive diagnostic measures. In addition, more microbiota and epigenetic therapies are now in preclinical stages of clinical trials, bringing a new era of precision medicine.

But these discoveries need to be taken to clinical use, which means that it must be a multidisciplinary effort, involve long-term cohorts, and have access to high-grade diagnostics. Applying multi-omic data (genomics, epigenomics, metabolomics, and microbiomics) into the clinical algorithm will be the key that will make precision hepatology possible. It also requires investment in bioinformatics infrastructure, educating clinicians, and

ethical models about how to practice personalized medicine.

The review represents not only a synthesis of the existing knowledge but also includes a strategic roadmap of future activities that may be relevant to research, policy, and clinical innovation of NAFLD. The first step toward achieving the paradigm shift in care of individuals with this disease is the realization of its individual complexity.

Future Projections and What This Review May Bring Aboard

The investigations expressed in this review highlight the movement of NAFLD studies away from fundamentally metabolism-oriented studies to multi-omics and systems biology research. With precision medicine still being in its developmental stages, it is expected that the incorporation of genetic, epigenetic, and microbial profiles into daily clinical routine is going to become expected. The main developments are anticipated in the nearest future:

1. Genomic Screening as a Means of Early Risk Detection:

The use of polygenic risk scores (PRS) that combine PNPLA3, TM6SF2, and other loci could be adopted on a population scale to fractionate people to be at risk of progressive NAFLD. This may facilitate an earlier intervention and monitoring, particularly in the high-risk ethnic groups.

2. Non-Invasive Diagnosis: Epigenetic Biomarkers:

The application of methylation signatures and circulating microRNA

will probably join or replace liver biopsy in diagnosing and monitoring the severity of NAFLD and response to treatment.

3. Microbiota-Driven Therapeutics:

Development of microbial-based therapeutics such as designer probiotics and postbiotics will pick up. Individual microbiome profiling can inform a targeted diet or pharmacological approach.

4. Intergenerational Prevention Models:

Epigenetic inheritance suggests the future implementation of public health policies in pursuit of maternal health and exposure to early-life factors. This can go a long way to eliminate the burden of NAFLD in the future.

5. Omics-Integrated Clinical Trials:

In the future, a multi-omic approach (i.e., genomics, epigenomics, metabolomics, and microbiomics) would be implemented in clinical trials to determine responders and non-responders to certain treatments and, therefore, enhance effectiveness and reduce adverse events.

How This Review Contributes:

Synopsis of Evidence: The review provides a unified overview of approximately 100 vital studies, which brings together recent discoveries concerning genetic, epigenetic, and microbial diseases in NAFLD.

Precision Medicine Framework: In terms of the exceptionality pointed to by gene-environment-microbiome interactions, the review can be used as a

conceptual framework applied by researchers during the development of individualized models of prevention and treatment.

Clinical Relevance:

This review highlights actionable information that outlines the usefulness of PNPLA3 genotyping, epigenetic biomarkers, and therapy that targets the gut by the clinicians.

The delta of genetic, epigenetic, and gut microbiome has the power to turn NAFLD, a traditional metabolic disease, into a disease susceptible to precision medicine. The clinical usefulness of these molecular discoveries is also tangible at various levels, i.e., at-risk prediction and diagnosis, prognosis, and treatment at individual levels.

5.1 Early Detection and Risk Stratification

Earlier and more profound intervention can be done with people identified as genetically predisposed to progressive NAFLD. As an example, the bearers of the PNPLA3 I148M and TM6SF2 E167K alleles have an increased susceptibility toward steatohepatitis, fibrosis, and hepatocellular carcinoma (Romeo et al., 2008; Liu et al., 2014). High-risk groups (e.g., diabetics, obese adolescents, and South Asians) could be genotyped, and this information could be built into clinical algorithms to inform how frequently imaging is repeated or lifestyle advice or pharmacologic monitoring is conducted.

5.2 Diagnosis and monitoring Noninvasive

The invasive quality of liver biopsy is one of the barriers towards early diagnosing liver diseases. The development of epigenetic biomarkers, including circulating microRNAs (miR-122, miR-34a) and methylation signatures, is reported in the development of blood-based test biomarkers to diagnose the presence of fibrosis and staging (Sookoian & Pirola, 2013). In many patients these biomarkers may be used instead of or along with biopsy in the near future with better patient safety and compliance.

5.3 Drug responsiveness and stratification therapy

Responsiveness to therapy has a relationship with genetic background. As an example, PNPLA3 carriers might not react to lifestyle modifications as well and could use anti-fibrotic agents or FXR agonists. The consideration of the genotype of the participants in clinical trials has been done to improve the therapeutic accuracy and better understand the efficacy of the drugs.

5.4 Personalization of nutrition and lifestyle

Individual risk profiles are resulting in the adaptation of nutritional strategies. The PNPLA3 carriers could be offered the strict control of sugar intakes; it could be better to offer low-carb diets to GCKR mutation carriers. Also, a gut microbiota-based approach to personalized probiotics, synbiotics, and prebiotics is a potential adjunct to lifestyle intervention, particularly in individuals with inflammatory features in their microbiome.

5.5 Tracking Regression and Progression of the Disease

As the evidence changes, the composition of the microbiota of the gut as well as epigenetic marks could be used as a measure of disease activity/remission over time. As an example, an increase in *Akkermansia muciniphila* and changes in the ratio of bile acids can indicate a microbiota-based enhancement. On the same note, reversal of methylation in major genes that are related to fibrosis would also indicate effectiveness of the therapy.

5.6 Future Clinical Trials and Therapeutic Targets

Drugs using FXR/TGR5 receptors, HDAC inhibitors, and miRNA antagonists are currently under new trials. The agents have the potential to reverse the hepatic inflammation, steatosis, and fibrosis in a pathway-specific manner. The idea behind multi-omic stratification in clinical trials could enhance the effectiveness of recruitment and reliability of outcomes that eventually lead to quick drug approvals.

Future Direction: The gaps and predictions presented here may guide future grant writing, experimental design, and translational research studies in hepatology and systems medicine.

Table 1:Gene and common Role

Gene/Enzyme	NAFLD	AFLD	Common Role / Note
PNPLA3 (I148M)	Strongly associated with increased liver fat	Also contributes to disease severity	Key in triglyceride hydrolysis in hepatocytes
TM6SF2	Associated with hepatic fat accumulation	Less studied in AFLD	Regulates lipid secretion from liver
MBOAT7	Affects phospholipid remodeling in NAFLD	Role less clear	Modifies inflammation and steatosis
GCKR	Promotes triglyceride synthesis via glycolysis	Not well linked	Regulates glucose metabolism
ADH1B/ALDH2	Rarely mutated in NAFLD	Strongly linked due to ethanol metabolism	Alcohol metabolism enzymes; polymorphisms affect susceptibility to AFLD
CYP2E1	Induced in obesity/diabetes (mildly)	Strongly induced by ethanol	Generates ROS, causes oxidative stress
SOD2	Impaired antioxidant response	Overwhelmed by alcohol-induced ROS	Mitochondrial antioxidant defense
TNF / IL6	Elevated in obesity-related inflammation	Elevated due to alcohol-induced endotoxemia	Drive inflammation and fibrosis
HSD17B13	Protective variant against NAFLD	Less protective in AFLD	Affects lipid droplet metabolism

Table 1:Enzyme and Role in Liver function

0	Protein/Enzyme Produced	Role in Liver Function
ALB	Albumin	Maintains oncotic pressure and transports hormones, drugs, and fatty acids
CYP3A4	Cytochrome P450 3A4	Drug metabolism and detoxification
F7	Coagulation factor VII	Blood clotting cascade
G6PC	Glucose-6-phosphatase	Final step in gluconeogenesis and glycogenolysis
HNF4A	Hepatocyte nuclear factor 4 alpha	Regulates genes involved in glucose, cholesterol, and lipid metabolism
APOB	Apolipoprotein B	Component of VLDL and LDL; essential in lipid transport
PCSK9	Proprotein convertase subtilisin/kexin 9	Regulates LDL receptor degradation, influences cholesterol levels
SOD2	Superoxide dismutase 2	Antioxidant defense in mitochondria
UGT1A1	UDP-glucuronosyltransferase 1A1	Conjugation of bilirubin for excretion
MTTP	Microsomal triglyceride transfer protein	Assists in VLDL assembly and lipid transport
PNPLA3	Patatin-like phospholipase domain-containing protein 3	Implicated in fat metabolism and steatosis, especially NAFLD
TNF	Tumor necrosis factor	Inflammatory cytokine involved in liver inflammation
IL6	Interleukin-6	Immune response and inflammation
NR1H3 (LXRα)	Liver X receptor alpha	Regulates lipid metabolism and cholesterol efflux

References

- 1 Romeo, S., ST, et al. (2008). The PNPLA3 genetic variation is the determining factor of nonalcoholic fatty liver disease. *Nature Genetics*, 40 (12): 1461-1465.
- 2 Liu, Y. L., et al. (2014). The variant of TM6SF2 rs58542926 is associated with the development of hepatic fibrosis among patients with non-alcoholic fatty liver disease. *Nature Commun* S5 4309 2014.
- 3 Speliotes, E. K., et al. (2011). Genome-wide association analysis defines nonalcoholic fatty liver disease-associated variants to affect different metabolic traits in a differential manner. *PLoS genetics*, 7(3), e1001324.
- 4 Luukkonen, P. K., et al., (2016). MBOAT7 polymorphism rs641738 causes liver hepatic phosphatidyl-inositols and predisposes to NAFLD-related liver fibrosis. *Journal of Hepatology* 65: 1263127565, 2021.
- 5 Abul-Husn, N. S., et al. (2018). A protection of a protein truncating variant of HSD17B13 against the chronic liver disease. *New England journal of medicine*, 378(12), 1096 1106.
- 6 Goodrich, J. K., and some friends (2016). The use of human genetics makes the gut microbiome. 159(4), 789799.
- 7 Zhou, D., et al. (2020). Liver regeneration in mice is disrupted by inhibition of histone deacetylase 3. *Hepatology*, 71(4),1304-1317.
- 8 Sookoian, S., Pirola, C. J. (2013). Epigenetic and DNA methylation in liver fat. *Hepatology* 59; 667-675.
- 9 Y. Chen, et al., (2018). The Supervision of the lncRNAs and circRNAs in liver fist. *Oncotarget*, 9(1): 11-11.
- 10 6. Loomba, R., et al. (2015). Hepatic fibrosis and steatosis: Heritability of the diseases according to a prospective study of twins. *Gastroteandrinologiya*, 149 (7), 1784-1793.e1.
- 11 7. Zain, S. M. et al. (2019). The genetic variants related to non alcoholic fatty liver disease are different amongst ethnic groups in Malaysian patients. *Genes & Nutrition*, 14(1):1 10.
- 12 8. M., Eslam, and others (2018). A new definition of metabolic dysfunction-associated fatty liver disease An international expert consensus statement. *Journal of Hepatology* 73.1: 202-209.
- 13 Q. M. Anstee, et al. (2020). Non-alcoholic fatty liver and steatohepatitis genome-wide Association in a histologically-defined population. *Journal of Hepatology*, vol 73, no 3, 505-515.
- 14 17. Le Roy, T. et. al. (2019). The microbiome in the intestine controls the cholesterol of the host. *BMC Biology* 17,1 (2019): 94.
- 15 18. J. Aron-Wisniewsky et al.(2020). Human NAFLD and gut microbiota: Untangling microbial compositions with metabolic reprehensions. *Nature Reviews gastroenterology and hepatology*. v.17., p.279-297.
- 16 19. Caussy, C., et al. (2019). The machine learning solution to forecast histological severity of nonalcoholic fatty liver disease: GOAL study. *Hepatology* (2007) 69, 861873, and.
- 17 Sookoian, S., and Pirola, C. J. (2020). Nonalcoholic fatty liver disease: Genetic and epigenetic sources of precision medicine. *Clinical, and Molecular Hepatology*, 26 (3) 280 293.
- 18 Younossi Z. M., et al. (2018). NAFLD, NASH: trends, predictions and risk factors and prevention: global burden. *Nature Reviews Gastroenterology & Hepatology*, vol.15, issue 1, p.11-20.
- 19 . Tilg, H., Moschen, A. R. (2014). The relationship between microbiota and diabetes: a symbiosis. *Gut*. 63(9), 1513 1521.
- 20 E. Buzzetti, et al. (2016). The multihit pathology of non-alcoholic fatty liver disease (NAFLD). *Metabolism*, vol. 65, No. 8, p. 1038- 1048; 2006.
- 21 24. Loomba, R., Friedman, S. L. (2021). Pathophysiology and pathogenic effects of nonalcoholic fatty liver disease. *Cell* 184, 10: 25372564 (2016).
- 22 Pirola, C. J., and Sookoian, S. (2016). The context ambivalence of the mitochondrial SIRT 3 in NAFLD. *Frontiers of Genetic*, 7: 33.
- 23 Vilar-Gomez, E., et al. (2015). The lifestyle modification of weight loss is a strong contributor to lowering nonalcoholic steatohepatitis characteristics. *GastrOenterology*, 149(2), 367378.
- 24 Hoyles, L., et al. (2018). Molecular phenomics and metagenomics of hepatic steatosis in non diabetic obese women. *Nature Medicine* (2018) 24, 1070 e1080.
- 25 Rinella, M. E. (2015). Nonalcoholic fatty liver disease: systematic review. 313 (22), 2263 2273.
- 26 Mann, J. P., Semple, R. K. (2020). Stages of NAFLD in children: an emerging issue. *Current Opinion in Pediatrics*, 32(4), pp.504 510.
- 27 Gaggini, M., et al. (2013). NAFLD and diabetes the two-way street.
- 28 Historical Feasibility of Time-limited Cure; CTB Research of the United States, *Liver International* 33(7) 10371048.
- 29 Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., ... A. J. Sanyal (2012). Diagnosis and Management of the Non alcoholic Fatty Liver Disease: Practice guideline of the American gastroenterological Association, American Association to the study of liver diseases and the American College of gastroenterology. *Hepatology*, 55(6) 2005-2023.

- 30 G. E. Arteel (2003). Alcohol-induced liver disease and oxidants and antioxidants. *Gastroenterology*, 124(3),
- 31 . Loomba, R., ; Sanyal, A. J. (2013). NAFLD pandemic in the world. *Nature Rev Gastroenterol Hepatol*. 2013 Mar;10(11):686-90.
- 32 . Rehm, J., et al. (2010). Worldwide disability-adjusted life years and cost burden occasioned by consumption of alcohol and alcohol-use disorders. *Lancet* 373(9682): 2223-2233.